A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
| Condition | Glioblastoma, Glioblastoma Multiforme |
|---|---|
| Phase | Phase 1 |
| Sponsor | Bryan Allen |
| Status | Active, not recruiting |
| Enrollment | 16 participants |
| Interventions | Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide |
| Start date | Feb 28, 2023 |
| Completion date | May 13, 2025 |
| Results posted | Jul 20, 2026 |
Summary
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)
| Cohort 1 | 2 Dose Limiting Toxicities |
|---|---|
| Cohort 2 | 0 Dose Limiting Toxicities |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed M — National Cancer Institute (NCI)